Prosecution Insights
Prosecution Insights
Technology area: Biotechnology & Pharmaceuticals
3 pending office actions • 1 art units • 3 examiners • 0 of 3 (0%) have an AI response strategy ready
Lundquist Institute For Biomedical Innovation AT Harbor-Ucla Medical Center has 3 pending office actions in the Biotechnology & Pharmaceuticals technology area. These 3 pending office actions are handled by 3 distinct examiners but are concentrated within 1 distinct art unit. This suggests that the institute's current patent applications are technically similar enough to be grouped together by the patent office, even though they are being reviewed by different individuals.
SHI, GENBIN is the busiest examiner for the portfolio, currently managing 1 pending office action. With 3 pending office actions and 3 distinct examiners involved, the institute faces different examiner perspectives within 1 distinct art unit. Practitioners should be prepared for separate prosecution tracks, as each examiner will bring their own interpretation to the pending matters within the Biotechnology & Pharmaceuticals space to secure patent rights.
Difficulty is derived from the rejection statutes on the most recent pending office action. §101-driven and multi-statute cases are graded Hard; §112-only and obviousness-type double-patenting cases are graded Easy; everything else is Medium. "Unknown" means we have not yet parsed a statute for that office action.
| Bucket | Cases |
|---|---|
| §112 only | 1 (33%) |
| Multi-statute (no §101) | 2 (67%) |
How the docket's pending cases split across USPTO tech-center bands.
Manual office-action response work runs about 10 hours per case. The time-saved bands below show what IP Author's prosecution pipeline typically delivers — a conservative 20% on the low end, 35% in the middle, 50% on the high end.
| Examiner | Apps on this docket | Allow rate | Interview lift |
|---|---|---|---|
| SHI, GENBIN | 1 | — | — |
| AGGARWAL, SAHIL CHANDER | 1 | 100.0% | +0.0% |
| JOHNSON, TIRONE DEREK | 1 | 0.0% | +0.0% |
Multi-statute / §101-driven matters, or cases in front of an examiner with an allow rate under 30%. The top 3 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18840042 | MODULATION OF HUMAN BREAST MILK COMPOSITION | SHI, GENBIN | — |
| 18743767 | Methods and Compositions for Treating Fibroids | AGGARWAL, SAHIL CHANDER | — |
| 18558138 | COTH3 BINDING AGENTS AND USES THEREOF | JOHNSON, TIRONE DEREK | — |
| Art Unit | Apps |
|---|---|
| 1674 | 1 |
| App # | Title | Examiner | Art Unit | Statutes | Status | Due in | AI | Filed |
|---|---|---|---|---|---|---|---|---|
| 18840042 | MODULATION OF HUMAN BREAST MILK COMPOSITION | SHI, GENBIN | — | §102§103§112 | Non-Final OA | — | Pending | Aug 20, 2024 |
| 18743767 | Methods and Compositions for Treating Fibroids | AGGARWAL, SAHIL CHANDER | — | §102§103§112 | Non-Final OA | — | Pending | Jun 14, 2024 |
| 18558138 | COTH3 BINDING AGENTS AND USES THEREOF | JOHNSON, TIRONE DEREK | 1674 | §112 | Non-Final OA | — | Pending | Oct 30, 2023 |
IP Author helps IP teams respond to office actions faster with AI-generated responses, examiner analytics, and prosecution intelligence.
Start Free Trial